Aspirin, IVIG, and Prednisolone Combination Therapy

This is a combination therapy consisting of three medications: aspirin, intravenous immunoglobulin (IVIG), and prednisolone. It has been primarily studied for the treatment of Kawasaki disease (KD), particularly in patients at high risk of developing coronary artery lesions (CAL) or coronary artery abnormalities (CAA)[1][2][5]. The combination works through multiple mechanisms: - **IVIG** provides immunomodulatory effects, neutralizing pathogenic autoantibodies and interacting with complement activation - **Prednisolone** (a corticosteroid) provides anti-inflammatory effects - **Aspirin** provides antiplatelet and anti-inflammatory properties Clinical trials have shown that this triple combination therapy significantly reduces the incidence of coronary artery abnormalities compared to standard treatment with IVIG plus aspirin alone[2][6]. The RAISE study demonstrated that adding prednisolone to the standard IVIG and aspirin regimen improved coronary artery outcomes in patients with Kawasaki disease at high risk of IVIG resistance[8].

Other names

Triple combination therapy for Kawasaki disease